🇺🇸 FDA
Patent

US 8586762

Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same

granted A61PA61P13/08A61P15/00

Quick answer

US patent 8586762 (Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same) held by Takeda Pharmaceutical Company Limited expires Mon Nov 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Nov 19 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61P, A61P13/08, A61P15/00, A61P17/14, A61P35/00